| Project/Area Number |
15K08591
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Kobe Gakuin University (2016-2017)
Kyushu University (2015) |
|---|
Principal Investigator |
IKESUE HIROAKI 神戸学院大学, 薬学研究科, 連携准教授 (60748010)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MASUDA Satohiro 九州大学, 大学病院, 教授 (90303825)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | がん / 骨転移治療薬 / ゾレドロン酸 / デノスマブ / 腎機能 / 癌骨転移治療薬 / 薬剤性腎障害 / 低カルシウム血症 / 副作用 |
|---|
| Outline of Final Research Achievements |
We performed a retrospective cohort study to asses the risk factors of kidney injury in 236 patients receiving zoledronic acid. The incidence of kidney injury was 13%. The multivariate analysis showed that diabetes mellitus, baseline lower kidney function, and concomitant use of cisplatin were significant risk factors for kidney injury. In addition, we experienced a case of acute kidney injury in a patient with metastatic malignant melanoma, receiving dabrafenib/trametinib combination therapy. We also retrospectively analyzed risk factors of osteonecrosis of the jaw (ONJ) in 397 patients receiving zoledronic acid or denosumab. The incidence of ONJ was 6%. The multivariate analysis showed that denosumab, older age, and concomitant use of anti-angiogenetic agents were significant risk factors for ONJ.
|
